Ernexa Therapeutics (NASDAQ:ERNA) Releases Quarterly Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) announced its quarterly earnings results on Monday. The company reported ($6.95) earnings per share (EPS) for the quarter, Zacks reports.

Ernexa Therapeutics Trading Up 6.8%

NASDAQ:ERNA traded up $0.82 during trading hours on Wednesday, reaching $12.83. 1,152,927 shares of the company traded hands, compared to its average volume of 1,117,616. The business’s 50-day moving average price is $5.99 and its two-hundred day moving average price is $20.68. The stock has a market capitalization of $14.96 million, a P/E ratio of -0.48 and a beta of 1.88. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $100.46.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ERNA shares. Brookline Capital Markets started coverage on Ernexa Therapeutics in a research report on Thursday, May 7th. They set a “buy” rating and a $30.00 price target on the stock. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a report on Monday. Wall Street Zen raised Ernexa Therapeutics to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ernexa Therapeutics has an average rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics News Roundup

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and maintained a $30 price target, which may have provided some support for the stock despite recent turbulence.
• Neutral Sentiment: The stock experienced multiple LULD pauses on May 12, indicating unusually high volatility and rapid price swings during the session.
• Negative Sentiment: Ernexa Therapeutics reported quarterly EPS of ($6.95), missing the consensus estimate of ($1.95) by a wide margin, which is a clear negative for investors.
• Negative Sentiment: Zacks Research downgraded Ernexa Therapeutics to Hold, suggesting analysts see less upside after the recent move in the shares. Zacks.com

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is owned by institutional investors.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.